Risperidone

Generic Name
Risperidone
Brand Names
Perseris, Risperdal, Rykindo, Uzedy, Okedi
Drug Type
Small Molecule
Chemical Formula
C23H27FN4O2
CAS Number
106266-06-2
Unique Ingredient Identifier
L6UH7ZF8HC
Background

Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. Paliperidone, another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone).
...

Indication

Risperidone is indicated for the treatment of schizophrenia and irritability associated with autistic disorder. It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.
...

Associated Conditions
Acute Mania, Irritability, Mixed manic depressive episode, Psychosis, Schizophrenia, Acute Manic episode, Agitated psychotic state
Associated Therapies
-
Clinical Trials
Related News

Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder

First Posted Date
2005-09-19
Last Posted Date
2010-05-04
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
130
Registration Number
NCT00190749
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States

Open-Label Comparative Study of Risperidone Versus Olanzapine Versus Quetiapine for Mania in Children and Adolescents With Bipolar I and Bipolar II Disorder

Phase 4
Completed
Conditions
Bipolar Spectrum Disorder
First Posted Date
2005-09-16
Last Posted Date
2013-06-13
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
106
Registration Number
NCT00182013

Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients

First Posted Date
2005-09-16
Last Posted Date
2015-06-10
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
107
Registration Number
NCT00183625
Locations
🇺🇸

West Los Angeles Veterans Healthcare Center, Los Angeles, California, United States

🇺🇸

Greater Manchester Mental Health Center, Manchester, New Hampshire, United States

Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar

Phase 3
Completed
Conditions
Bipolar Disorder
Interventions
Drug: risperidone
Drug: Divalproex Sodium
First Posted Date
2005-09-15
Last Posted Date
2015-11-05
Lead Sponsor
University of Illinois at Chicago
Target Recruit Count
65
Registration Number
NCT00176202
Locations
🇺🇸

Neuro Psychiatric Institute (NPI), Chicago, Illinois, United States

🇺🇸

NPI, Chicago, Illinois, United States

🇺🇸

NPI, University of Illinois at Chicago, Chicago, Illinois, United States

Risperidone Augmentation Therapy in Patients Who Have Failed or Only Partially Responded to a Trial of Antidepressant

Phase 3
Conditions
Major Depression
First Posted Date
2005-09-15
Last Posted Date
2005-09-15
Lead Sponsor
Rhode Island Hospital
Target Recruit Count
84
Registration Number
NCT00174577
Locations
🇺🇸

Mood Disorders Program - Rhode Island Hospital, Providence, Rhode Island, United States

🇺🇸

Emory University School of Medicine, Atlanta, Georgia, United States

Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study

Phase 4
Completed
Conditions
Bipolar Disorder
First Posted Date
2005-09-15
Last Posted Date
2005-09-15
Lead Sponsor
University of Pittsburgh
Target Recruit Count
60
Registration Number
NCT00177567
Locations
🇺🇸

University of Pittsubrgh Medical Center, Pittsburgh, Pennsylvania, United States

🇺🇸

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Risperidone (Risperdal) Augmentation in Depressed Partial Responders to SRI Treatment

Phase 4
Withdrawn
Conditions
Treatment Resistant Depression
First Posted Date
2005-09-15
Last Posted Date
2017-04-04
Lead Sponsor
Vanderbilt University Medical Center
Registration Number
NCT00178854
Locations
🇺🇸

Vanderbilt University Medical Center, Nashville, Tennessee, United States

Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms

Not Applicable
Completed
Conditions
Prodromal Schizophrenia
Psychotic Disorders
First Posted Date
2005-09-15
Last Posted Date
2009-12-17
Lead Sponsor
Northwell Health
Target Recruit Count
8
Registration Number
NCT00169988
Locations
🇺🇸

RAP Program, Dept. of Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks, New York, United States

Treatment of Major Depressive Disorder With Psychotic Features.

Phase 3
Terminated
Conditions
Major Depression With Psychotic Features
First Posted Date
2005-09-15
Last Posted Date
2008-01-10
Lead Sponsor
Rush University Medical Center
Target Recruit Count
30
Registration Number
NCT00174590
Locations
🇺🇸

Rush University Medical Center, Chicago, Illinois, United States

Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD)

Phase 1
Completed
Conditions
Child Development Disorders, Pervasive
First Posted Date
2005-09-14
Last Posted Date
2014-01-28
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
100
Registration Number
NCT00166595
Locations
🇺🇸

The Ohio State University Medical Center, Columbus, Ohio, United States

🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

🇺🇸

Children's Hospital of Michigan/Wayne State University, Detroit, Michigan, United States

and more 1 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy